Body composition change indices combined with Prognostic Nutritional Index predicts the clinical outcomes of patients with gastric cancer treated with immune checkpoint inhibitor

Documenti analoghi

• CD3+/CD4+ cells combined with myosteatosis predict the prognosis in patients who underwent gastric cancer surgery
  di: Zhongze Du, et al.
  Pubblicazione: (2024)
• Impact of immune checkpoint inhibitors on survival outcomes in advanced gastric cancer in Japan: A real‐world analysis
  di: Toru Kadono, et al.
  Pubblicazione: (2024)
• Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors
  di: Tadashi Nishimura, et al.
  Pubblicazione: (2024)
• Inconsistency in steroid use as antiemetics in clinical trial protocols involving immune checkpoint inhibitors combined with chemotherapy
  di: Soh Mee Park, et al.
  Pubblicazione: (2024)
• Analysis of the clinical efficacy and safety of anti‐PD‐1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer
  di: Shuling Shi, et al.
  Pubblicazione: (2024)